Recipharm Reaches Agreement with LobSor Pharmaceuticals
News Sep 10, 2015
Recipharm and LobSor Pharmaceuticals have announced the formation of a manufacturing agreement for LECIGON™.
As part of the agreement, Recipharm will have exclusive manufacturing rights for volumes representing first three years of commercial sales. Recipharm will also support development costs against a mark-up on manufacturing prices, up to a certain volume, when LECIGON is produced for commercial sales.
This agreement is a follow-on to an established collaboration between LobSor and Recipharm for the development and the manufacturing of batches for the recently completed clinical trial.
Carl-Johan Spak, EVP Development & Technology, Recipharm, commented: “We are extremely pleased to have developed our collaborative partnership with LobSor Pharmaceuticals and to have signed an agreement for the future commercial manufacturing of LECIGON, especially as this is a new, innovative drug, which we believe provides a clear benefit to patients with advanced Parkinson’s disease.”
Roger Bolsöy, Managing Director of LobSor Pharmaceuticals said “It is well known that pharmaceutical development is costly and can be cumbersome for a small company. Recipharm is one of our most important strategic partners for the development of our first pharmaceutical product, with whom we have been able to find creative collaboration models to secure the initiation of the LECIGON project. I am impressed that such a large organization as Recipharm has been able to show such entrepreneurial spirit and flexibility to facilitate the development of a company from the early stages through to commercialization”.
Autism Risk Higher if Pregnant Mothers Have Infection Requiring HospitalizationNews
Studies have shown that mothers who experience an infection severe enough to require hospitalization during pregnancy are at higher risk of having a child with autism.READ MORE
Flow Chemistry Process Development: Johnson Matthey and Snapdragon Chemistry Announce PartnershipNews
Johnson Matthey and Snapdragon Chemistry Inc. are pleased to announce that they have entered in to a collaborative agreement to provide integrated continuous manufacturing services – from development to full-scale GMP manufacturing.READ MORE
Ebola Vaccination: Study Assessing Immune Response Fuels Improved Vaccine DevelopmentNews
DZIF scientists were successful in their study, assessing early on, the longer-term immune response in humans after being vaccinated with the newly developed Ebola vaccine “rVSV-ZEBOV“.READ MORE